stockrowHaleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) Total debt
Haleon PLC Sponsored ADR's total debt at the end of fiscal 2025 was $11.4B, down 12.3% from $12.9B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $11.1B. Over the past ten years it has ranged from $667.1M (fiscal 2020) to $12.9B (fiscal 2024); the current reading is higher than 57% of that period. Haleon PLC Sponsored ADR ranks 3rd of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $11.4B | (12.28%) |
| FY2024 | $12.9B | 10.02% |
| FY2023 | $11.8B | (8.91%) |
| FY2022 | $12.9B | 864.26% |
| FY2021 | $1.3B | 100.74% |
| FY2020 | $667.1M | (21.03%) |
| FY2019 | $844.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $11.1B | (2.20%) |
| Jun 2025 | $11.3B | 1.30% |
| Jun 2024 | $11.2B | (9.49%) |
| Jun 2023 | $12.4B | (4.35%) |
| 2 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $28.8B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $16.7B |
| HLN Haleon PLC Sponsored ADR | $11.1B |
| ZTS Zoetis Inc. compare | $9.0B |
| ELAN Elanco Animal Health Incorporated compare | $3.9B |
| VTRS Viatris Inc. compare | $1.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $753.0M |
| NBIX Neurocrine Biosciences, Inc. compare | $274.0M |
| UTHR United Therapeutics Corporation compare | $200.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement